Trial intelligence / Profile preview

Fampridine-SR for Spasticity in Spinal Cord Injury

NCT01683838Phase 3Completed

Sponsor
Acorda Therapeutics
Start
Jun 2002
Primary completion
Nov 2003
Modality
Small Molecules
Countries
2
01

Overview

A Phase 3 trial of dalfampridine in spasticity, sponsored by Acorda Therapeutics. Started Jun 2002; status: completed.

02

Drugs

dalfampridine
03

Conditions

spasticity

Beyond the preview

Go deeper on NCT01683838.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01683838.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call